ImmunityBio, Inc. (IBRX)
IBRXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$7.13
-1.51 (-17.43%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $7.54bn
- P/E
- –
- EPS, last 4 quarters
- $-0.3000
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.95 to $12.43
- Average volume
- 12.23m
- Previous close
- $8.64
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $14.25, +99.9% from here
Earnings
next estimate $-0.0800Next report Nov 10, 2026
Sep 2025
+30.0%
Dec 2025
+25.0%
Mar 2026
-12.5%
Jun 2026
+11.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $32.06m | $38.28m | $44.21m | $51.24m |
| Gross profit | $31.88m | $37.90m | $43.97m | $50.94m |
| Operating income | -$55.63m | -$64.68m | -$69.79m | -$61.70m |
| Net income | -$67.25m | -$61.94m | -$632.78m | -$230.38m |
Last four quarters: revenue $165.79m, margin -598.6%, free cash flow -$288.07m
News
8 latest- ImmunityBio, Inc. Reports Q3 2026 Net Product Revenue of $48.7 Million and FDA Label Expansion for ANKTIVAFintel · 8 hours ago
- ImmunityBio, Inc. Announces ANKTIVA Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 TrialFintel · 12 hours ago
- ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue EstimatesZacks · 13 hours ago
- Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock DownZacks · 3 days ago
- SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales DeclineZacks · 4 days ago
- ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock UpZacks · 4 days ago
- Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/Y Zacks · 5 days ago
- AMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance RaisedZacks · 6 days ago
The company
ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 receptor agonist, ANKTIVA (nogapendekin alfa inbakicept-plmn).
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- immunitybio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.